Triple Therapy With Calcineurin Inhibition Enhances Remission in Childhood-Onset Lupus Nephritis

Kidney International Reports 2026 Open access

Read full text
Authors: Kyle Ying‐kit Lin, Xuhui Zhong, Dong‐Yang Zhou, Andrea Angeletti, Luca Antonucci, Wei Bai, Liangjian Lu, Xiao-yu Liu, Stephen D. Marks, Sanjukta Poddar, Rajiv Sinha, Sharon Teo
+3 more Marina Vivarelli, H. K. Yap, Eugene Yu-hin Chan
DOI: 10.1016/j.ekir.2026.106485
Cited by: 2
References: 8

Abstract

Triple therapy, adding calcineurin inhibitors (CNIs) to corticosteroids and MMF, is a promising treatment in lupus nephritis (LN)1,2. CNIs inhibit interleukin-2 secretion and T-cell proliferationS1, and lower proteinuria by stabilising podocyte cytoskeletonS2. In AURORA, add-on voclosporin improved adult LN remission3. Nevertheless, it remains untested in paediatric patients, with uncertain long-term safety and limited global access.

Fields of Study & Subjects

Signaling Pathways in Disease Systemic Lupus Erythematosus Research Natural Compounds in Disease Treatment

Publication details

Journal / source
Kidney International Reports
Publisher
Elsevier BV
Volume
11
Issue
6
Pages
106485–106485
Publication date
18 March 2026
Language
EN